Denali Therapeutics Inc. research snapshot
DNLI AI stock analysis reads Denali Therapeutics Inc. as a commercial-stage biotech following the March 25, 2026 accelerated approval of AVLAYAH (tividenofusp alfa) for Hunter syndrome, the first FDA-approved medicine designed to cross the blood-brain barrier. At the August 3, 2026 data cutoff the intraday quote was $23.30, market capitalization was about $3.70 billion, and the main decision point was whether the AVLAYAH launch ramp, the August 6, 2026 Q2 report, and end-2026 pipeline data can justify the valuation while cash burn continues. The June 2026 LUMA Phase 2b miss in the Biogen-partnered Parkinson program is the clearest recent negative. This page uses a scenario framework, not a certain price prediction, and is informational research rather than investment advice.
Current price
$23.30
Market cap
$3.70 billion
AI score
58 / 100
Rating
Approved product with launch momentum, high pipeline and cash burn risk
Trend status
Pullback from the 52-week high, holding above the 200-day average
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Denali became a commercial-stage biotech after the March 25, 2026 accelerated approval of AVLAYAH for Hunter syndrome, with a U.S. launch underway and first patients treated in April. Recurring product revenue is still early and the August 6 Q2 report will show the first revenue detail. | Medium |
| Moat | The moat is built on the TransportVehicle platform, validated as the first FDA-approved medicine designed to cross the blood-brain barrier via transferrin receptor. Patents, clinical data, and manufacturing know-how support it, but durability depends on confirmatory and pipeline evidence. | Low-medium |
| Management | Founder-led with scientific depth. The team monetized the Rare Pediatric Disease PRV for $195 million, secured $200 million from Royalty Pharma, and kept Q1 R&D spending in check. The LUMA Phase 2b miss and the Takeda exit show program-level execution risk remains. | Medium |
| Financial trend | Q1 2026 net loss was $128.4 million versus $133.0 million a year earlier, R&D was $103.8 million, and cash plus marketable securities was about $1.05 billion at March 31, 2026. TTM net loss is about $508 million with a $412 million operating cash outflow. | High |
| Valuation | Market cap near $3.70 billion and enterprise value near $2.64 billion, with net cash of about $1.01 billion or $6.37 per share. P/E is not meaningful with negative EPS, so the price mostly reflects AVLAYAH launch option value and the pipeline. | Medium |
| Technical trend | The stock pulled back from a $27.30 July high to near the 50-day average around $22.98 while holding above the 200-day average near $19.88. RSI near 45 suggests a neutral short-term read. | Medium |
| Risk level | High. The thesis can fail if AVLAYAH revenue disappoints, COMPASS confirmatory data is negative, DNL593 or DNL126 data misses, partnerships exit further, or cash burn forces dilutive financing. | High |
| AI confidence | High for reported financials, the quote, market cap, and analyst consensus. Lower confidence for forward returns on a biotech with pending launch and pipeline catalysts. | Medium data confidence |
| Investment certainty | Low-medium. The page provides a scenario framework, not a personalized buy or sell instruction, for a stock with binary commercial and clinical outcomes. | Low-medium |
DNLI AI stock forecast
The DNLI AI stock forecast uses scenario ranges rather than a point target. Denali now has one approved product, AVLAYAH, and a pipeline that includes DNL593 (FTD-GRN data expected end of 2026) and DNL126 (BLA path targeted in 2027), but the June LUMA Phase 2b miss shows clinical risk is real. The 20-analyst consensus is Strong Buy with an average target of $34.31 and a range of $25 to $42.
$30.00 to $38.00
More likely if the August 6 Q2 report shows a strong AVLAYAH launch ramp, COMPASS study progress builds confirmatory evidence, DNL593 FTD-GRN data at the end of 2026 is positive, and the DNL126 2027 BLA path stays on track. Analyst targets in the $36 to $42 range would then become the reference.
$23.00 to $29.00
More likely if AVLAYAH grows steadily but gradually, pipeline data is mixed without a binary-negative event, and the stock consolidates around current levels while the market waits for Q2 revenue detail and the end-2026 readouts.
$16.00 to $22.00
More likely if AVLAYAH launch underwhelms, COMPASS or DNL593 or DNL126 data disappoints, further partner exits or dilution appear, or the stock breaks below the 200-day moving average near $19.88.
DNLI AI technical analysis
DNLI AI technical analysis starts from the $23.30 intraday quote on August 3, 2026, with a July 31 close of $23.02. The stock peaked at $27.30 on July 9, then fell roughly 14% in one July 14 session on heavy volume before settling in the $22 to $24 zone. As of the cutoff, price sat below the 50-day moving average near $22.98 and above the 200-day moving average near $19.88, with RSI near 45. This static page does not fetch request-time chart data, so moving averages and momentum should be confirmed in a charting tool before use.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $23.30 | Intraday quote on August 3, 2026; July 31 close was $23.02. Used for market cap and valuation math. |
| Near support | $22.00 to $23.00 | The mid-July low area and the 50-day moving average near $22.98 form the first support band to monitor. |
| Secondary support | $19.45 to $20.00 | The June low area and the 200-day moving average near $19.88 mark the next downside reference. |
| Near resistance | $24.35 to $25.00 | The late-July highs around $24.35 to $24.68 are the first upside hurdle. |
| Secondary resistance | $26.50 to $27.30 | The July 9 high of $27.30 is also the 52-week high and the outer upside reference. |
| 50-day moving average | $22.98 | StockAnalysis statistics as of August 3, 2026. Price is trading just below this level. |
| 200-day moving average | $19.88 | StockAnalysis statistics as of August 3, 2026. This is the medium-term trend line. |
| Momentum | Neutral to slightly weak | RSI near 45.30 with price below the 50-day average and above the 200-day average implies a consolidation phase. |
| Volume | Elevated on selloff days | The July 14 session printed about 5.78 million shares versus a 20-day average near 1.64 million, showing news-driven spikes. |
| Volatility | High biotech volatility | Beta is near 0.96 and short interest is about 10.10% of shares outstanding, so clinical and earnings events can move the stock sharply. |
| Invalidation | Close below $19.88 | A decisive break below the 200-day moving average would weaken the medium-term uptrend. A close below $22.00 raises near-term downside risk. |
DNLI AI trading strategy
The DNLI AI trading strategy is a rules-based research framework, not personalized advice. It should be paired with live quotes, position sizing, the August 6 Q2 earnings event, AVLAYAH launch data, the clinical calendar, and cash runway monitoring.
Watch for DNLI to reclaim and hold the 50-day moving average near $22.98 on confirming volume, with the 200-day moving average near $19.88 as the medium-term trend filter.
A close back below $22.00 should reduce confidence. A close below the 200-day moving average near $19.88 would require a full trend and thesis reset.
If DNLI pulls back toward the $22.00 to $23.00 support band without a thesis break, compare the price drop with fresh evidence on the AVLAYAH launch, the August 6 Q2 report, and upcoming pipeline data before treating it as noise.
Do not average down without a predefined maximum loss and a fresh review of clinical and commercial risk. The LUMA Phase 2b miss shows a support level can become a fundamental break.
Track AVLAYAH launch revenue and payer access, COMPASS confirmatory study progress, DNL593 FTD-GRN data at the end of 2026, the DNL126 BLA path, cash runway, PRV and Royalty Pharma proceeds, and partnership status.
Reduce confidence when price moves are driven by speculation without matching clinical or commercial evidence.
Investment research summary
Denali sells medicines engineered to cross the blood-brain barrier. AVLAYAH is its first approved product, an enzyme replacement therapy for Hunter syndrome, and the TransportVehicle platform is the technology that lets large biologic drugs reach the brain.
The moat rests on the TV platform, validated as the first FDA-approved medicine designed to cross the BBB via transferrin receptor, plus patents, clinical data, and manufacturing know-how. Competitors such as Biogen, Lilly, Roche, and Ionis are building their own BBB and CNS approaches, so durability is not guaranteed.
The thesis can fail if AVLAYAH launch revenue disappoints, COMPASS confirmatory data is negative, DNL593 or DNL126 data misses, partnership exits continue after Takeda and the LUMA setback, or cash burn forces dilutive financing at unfavorable prices.
Founder Ryan Watts (CEO) and co-founder Alexander Schuth (COO and CFO) lead a science-first team. Capital allocation has been disciplined: monetizing the PRV for $195 million, raising $200 million from Royalty Pharma, and keeping Q1 R&D spending stable. The LUMA Phase 2b miss and the Takeda exit are the main execution questions.
Neurodegenerative and lysosomal storage disease is a large unmet medical need driven by an aging population. The BBB has historically blocked biologics from the brain, so a validated delivery platform sits in a favorable long-term position, even as competition and clinical failure rates remain high.
At about $3.70 billion market cap with negative EPS, P/E provides no margin-of-safety signal. Enterprise value near $2.64 billion and net cash of about $6.37 per share cushion part of the downside, but the rest of the valuation depends on AVLAYAH launch execution and binary pipeline outcomes.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| DNLI price | $23.30 intraday on August 3, 2026; July 31 close $23.02 | StockAnalysis.com quote snapshot | August 3, 2026 |
| Market capitalization | $3.70 billion, verified as $23.30 x 158.71 million shares | financial_rigor.py and StockAnalysis market cap data | August 3, 2026 |
| Enterprise value | $2.64 billion | StockAnalysis.com statistics | August 3, 2026 |
| Shares outstanding | 158.71 million shares; float 151.37 million | StockAnalysis.com statistics | August 3, 2026 |
| 52-week range | $12.58 to $27.30; +70.98% over the past year | StockAnalysis.com overview and history | August 3, 2026 |
| Net income (TTM) | -$508.02 million | StockAnalysis.com statistics | August 3, 2026 |
| EPS (TTM) | -$2.88; P/E not meaningful | StockAnalysis.com statistics | August 3, 2026 |
| Cash and net cash | Cash and equivalents $987.68 million; net cash about $1.01 billion ($6.37 per share) | StockAnalysis.com statistics | August 3, 2026 |
| Book value per share | $5.84; price-to-book ratio near 3.94 | StockAnalysis.com statistics | August 3, 2026 |
| Q1 2026 results | Net loss $128.4 million; R&D $103.8 million; cash and marketable securities about $1.05 billion at March 31, 2026 | Denali Q1 2026 press release via GlobeNewswire | August 3, 2026 |
| AVLAYAH approval | Accelerated approval March 25, 2026 for Hunter syndrome; U.S. launch with first patients treated commercially in April 2026 | Denali Q1 2026 press release via GlobeNewswire | August 3, 2026 |
| PRV sale | Definitive agreement to sell Rare Pediatric Disease PRV for $195 million gross proceeds, announced June 18, 2026 | Denali press release via GlobeNewswire | August 3, 2026 |
| LUMA Phase 2b result | BIIB122 (LRRK2 inhibitor) Parkinson study with Biogen did not meet Phase 2b endpoints | StockAnalysis.com news feed citing TheFly and Biogen | August 3, 2026 |
| Analyst consensus | Strong Buy; 20 analysts; average target $34.31; range $25 to $42 | StockAnalysis.com forecast | August 3, 2026 |
| Moving averages and momentum | 50-day moving average $22.98; 200-day moving average $19.88; RSI 45.30; beta 0.96 | StockAnalysis.com statistics | August 3, 2026 |
| Short interest | 16.04 million shares, 10.10% of shares outstanding, 7.65 days to cover | StockAnalysis.com statistics | August 3, 2026 |
| Next earnings date | August 6, 2026, after market close | StockAnalysis.com overview and Denali press release via GlobeNewswire | August 3, 2026 |
This DNLI AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available data as of August 3, 2026, may be incomplete, and can be wrong if AVLAYAH launch revenue, clinical trial results, regulatory decisions, partnership changes, financing events, market conditions, or company events change after the data cutoff.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
